{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-018071","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2024-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.027203+00:00","generated_at":"2026-06-06T15:58:29.990279+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Quince Therapeutics no salary increase for 2024; option grants to officers","bullets":["No salary increase for executive officers in 2024; Committee approved stock option grants.","CEO Dirk Thye: $302,500 bonus, 1,500,000 options vesting monthly over 4 years.","President Charles Ryan: $70,000 bonus, 145,000 options; COO Brendan Hannah: $178,500 bonus, 600,000 options.","Option grants effective Feb 1, 2024 under 2019 Equity Incentive Plan; vesting over 4 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-018071","json":"https://secwatch.observer/filing/0001193125-24-018071.json","markdown":"https://secwatch.observer/filing/0001193125-24-018071.md","text":"https://secwatch.observer/filing/0001193125-24-018071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312524018071/0001193125-24-018071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312524018071/d661573d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:58:29.990279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}